Cannot redeclare control with same name "grid_6_section_title_style"
PlexusDx screens for contraindications during intake and adjusts your protocol accordingly
This research was also supported by European Union - NextGenerationEU financing the PNRR Mission 4, Component 2 From Research to Business Investment 1.4 Strengthening research infrastructures and creation of national R&D champions on some Key Enabling Technologies, Project Code CN00000033, Spoke 8, titled National Biodiversity Future Center (NBFC)
Price vs Value Analysis Best Value Indicators: Transparent pricing (all costs clear upfront) Comprehensive inclusions (consultation, medication, supplies, shipping, follow-ups) Licensed providers (verifiable credentials) FDA-registered pharmacies (legitimate compounding) Good customer reviews (proven track record) Accessible support (responsive to questions/issues) Poor Value Indicators: Hidden fees (consultation separate, supplies extra, shipping charged) Excessive pricing ($650+/month for same medication) Pushy sales tactics (pressure to buy, urgency claims) Unclear provider credentials (cant verify licenses) Vague pharmacy information (wont disclose sources) Poor reviews (complaints about quality, service) Comparing to Brand-Name Costs Brand-Name Pricing (Without Insurance): Mounjaro: $1,069/month ($12,828/year) Zepbound: $1,069/month ($12,828/year) Compounded Tirzepatide: Low-cost: $349/month ($4,188/year) Mid-range: $500/month ($6,000/year) High-end: $650/month ($7,800/year) Annual Savings: Low-cost compounded: $8,640 savings Mid-range compounded: $6,828 savings High-end compounded: $5,028 savings Even the most expensive compounded option saves $5,000+ annually
Submit a packet, not just a form Include chart notes, recent weight, relevant labs, medication history, and supporting diagnosis details together
